Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.95|
|52 Week High||AU$0.56|
|52 Week Low||AU$1.03|
|1 Month Change||-1.04%|
|3 Month Change||9.14%|
|1 Year Change||66.09%|
|3 Year Change||4.37%|
|5 Year Change||-54.31%|
|Change since IPO||-49.87%|
Recent News & Updates
Should You Think About Buying Monash IVF Group Limited (ASX:MVF) Now?
Monash IVF Group Limited ( ASX:MVF ), might not be a large cap stock, but it saw a significant share price rise of over...
Monash IVF Group (ASX:MVF) May Have Issues Allocating Its Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Is Monash IVF Group Limited (ASX:MVF) Expensive For A Reason? A Look At Its Intrinsic Value
Today we will run through one way of estimating the intrinsic value of Monash IVF Group Limited ( ASX:MVF ) by taking...
|MVF||AU Healthcare||AU Market|
Return vs Industry: MVF exceeded the Australian Healthcare industry which returned 13.1% over the past year.
Return vs Market: MVF exceeded the Australian Market which returned 21.4% over the past year.
Stable Share Price: MVF is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: MVF's weekly volatility (3%) has been stable over the past year.
About the Company
Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The company offers diagnostic obstetric, gynecological ultrasound, and fertility research and treatment services. It also provides tertiary level prenatal diagnostic and IVF treatment services.
Monash IVF Group Fundamentals Summary
|MVF fundamental statistics|
Is MVF overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MVF income statement (TTM)|
|Cost of Revenue||AU$117.21m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.065|
|Net Profit Margin||13.70%|
How did MVF perform over the long term?See historical performance and comparison
4.4%Current Dividend Yield
Is Monash IVF Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MVF (A$0.96) is trading below our estimate of fair value (A$1.57)
Significantly Below Fair Value: MVF is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MVF is good value based on its PE Ratio (14.8x) compared to the Australian Healthcare industry average (24.7x).
PE vs Market: MVF is good value based on its PE Ratio (14.8x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: MVF is poor value based on its PEG Ratio (7x)
Price to Book Ratio
PB vs Industry: MVF is good value based on its PB Ratio (1.4x) compared to the AU Healthcare industry average (2.2x).
How is Monash IVF Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MVF's forecast earnings growth (2.1% per year) is above the savings rate (1.9%).
Earnings vs Market: MVF's earnings (2.1% per year) are forecast to grow slower than the Australian market (11.5% per year).
High Growth Earnings: MVF's earnings are forecast to grow, but not significantly.
Revenue vs Market: MVF's revenue (3.7% per year) is forecast to grow slower than the Australian market (5.3% per year).
High Growth Revenue: MVF's revenue (3.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MVF's Return on Equity is forecast to be low in 3 years time (9%).
How has Monash IVF Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MVF has high quality earnings.
Growing Profit Margin: MVF's current net profit margins (13.7%) are higher than last year (8.1%).
Past Earnings Growth Analysis
Earnings Trend: MVF's earnings have declined by 12.3% per year over the past 5 years.
Accelerating Growth: MVF's earnings growth over the past year (114.5%) exceeds its 5-year average (-12.3% per year).
Earnings vs Industry: MVF earnings growth over the past year (114.5%) exceeded the Healthcare industry 61.3%.
Return on Equity
High ROE: MVF's Return on Equity (9.5%) is considered low.
How is Monash IVF Group's financial position?
Financial Position Analysis
Short Term Liabilities: MVF's short term assets (A$22.5M) do not cover its short term liabilities (A$41.1M).
Long Term Liabilities: MVF's short term assets (A$22.5M) do not cover its long term liabilities (A$41.2M).
Debt to Equity History and Analysis
Debt Level: MVF's debt to equity ratio (0.6%) is considered satisfactory.
Reducing Debt: MVF's debt to equity ratio has reduced from 61.3% to 0.6% over the past 5 years.
Debt Coverage: MVF's debt is well covered by operating cash flow (2704.4%).
Interest Coverage: MVF's interest payments on its debt are well covered by EBIT (13.9x coverage).
What is Monash IVF Group current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MVF's dividend (4.4%) is higher than the bottom 25% of dividend payers in the Australian market (2.27%).
High Dividend: MVF's dividend (4.4%) is low compared to the top 25% of dividend payers in the Australian market (5.31%).
Stability and Growth of Payments
Stable Dividend: MVF has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: MVF has only been paying a dividend for 7 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (65.1%), MVF's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: MVF's dividends in 3 years are forecast to be covered by earnings (69.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Michael D. Knaap serves as Chief Executive Officer, Managing Director and Director of Monash IVF Group Limited since April 15, 2019. Mr. Knaap served as an Interim Chief Executive Officer of Monash IVF...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD680.12K) is about average for companies of similar size in the Australian market ($USD559.78K).
Compensation vs Earnings: Michael's compensation has increased by more than 20% in the past year.
Experienced Management: MVF's management team is considered experienced (2.8 years average tenure).
Experienced Board: MVF's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Monash IVF Group Limited's employee growth, exchange listings and data sources
- Name: Monash IVF Group Limited
- Ticker: MVF
- Exchange: ASX
- Founded: 2014
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: AU$362.360m
- Shares outstanding: 389.63m
- Website: https://www.monashivfgroup.com.au
Number of Employees
- Monash IVF Group Limited
- Pelaco Building 1
- Level 1
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/22 07:05|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.